Loading
A phase 3 trial of Orelabrutinib, Bendamustine, Rituximab in mantle cell lymphoma, run by InnoCare Pharma Inc., now recruiting.
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL is a phase 3 interventional study registered as NCT06363994 by InnoCare Pharma Inc., with 476 participants planned, started 2024-05-29 and due to reach its primary completion in 2031-06-25. Interventions recorded: Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo. Conditions listed: Mantle Cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Orelabrutinib, InnoCare Pharma, Small-molecule kinase inhibitors.
Shares Orelabrutinib, InnoCare Pharma, Rituximab, Monoclonal antibodies.
Shares Bendamustine, Rituximab, Mantle cell lymphoma, Monoclonal antibodies.
Shares Bendamustine, Rituximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Bendamustine, Rituximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Bendamustine, Rituximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Rituximab, Mantle cell lymphoma, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares InnoCare Pharma, Mantle cell lymphoma.